Literature DB >> 7332726

Pharmacokinetics of the enantiomers of acenocoumarol in man.

J Godbillon, J Richard, A Gerardin, T Meinertz, W Kasper, E Jähnchen.   

Abstract

1 The pharmacokinetics of R(+)-, S(-)- and R,S(+/-)-acenocoumarol were studied in healthy volunteers after administration of single oral and intravenous doses. 2 After both oral and i.v. administration of either enantiomer in a dose of 0.25 mg/kg, the concentrations of R(+) found in the plasma were much higher than those of S(-). This indicates that the observed differences are not related to stereoselective absorption. 3 After intravenous administration of 25 mg of each enantiomer and the racemate, the total plasma clearance of S(-) was about 10 times that of R(+). The clearance of the racemate was between that of the enantiomers. 4 The apparent elimination half-life of S(-) was much shorter than those of R(+) and the racemate, which were similar. 5 The apparent volume of distribution VdSS of S(-) acenocoumarol was 1.5 to 2 times that of R(+). 6 Measurements of the extent of binding to serum proteins, made in vitro at much higher concentrations than those observed in vivo, revealed no differences between the two enantiomers and the racemate. 7 The results indicate that the greater anticoagulant potency of R(+) compared with S(-) acenocoumarol can be explained mainly by stereoselective differences in their metabolic clearance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332726      PMCID: PMC1401957          DOI: 10.1111/j.1365-2125.1981.tb01280.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  The plasma elimination of the enantiomers of phenprocoumon in man.

Authors:  D S Hewick; A M Shepherd
Journal:  J Pharm Pharmacol       Date:  1976-03       Impact factor: 3.765

2.  Studies on the optical enantiomorphs of warfarin in man.

Authors:  R A O'Reilly
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

3.  Relationship between the kinetics of the anticoagulant effects of racemic warfarin and its individual enantiomers in man.

Authors:  G Levy; R A O'Reilly; L B Wingard
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-02

4.  Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.

Authors:  A Breckenridge; M Orme; H Wesseling; R J Lewis; R Gibbons
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

5.  Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols.

Authors:  R J Lewis; W F Trager; A J Robinson; K K Chan
Journal:  J Lab Clin Med       Date:  1973-06

6.  Optical studies on the mechanism of the interaction of the enantiomers of the antiocagulant drugs phenprocoumon and warfarin with human serum albumin.

Authors:  N A Brown; E Jähnchen; W E Müller; U Wollert
Journal:  Mol Pharmacol       Date:  1977-01       Impact factor: 4.436

7.  Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man.

Authors:  D S Hewick; J McEwen
Journal:  J Pharm Pharmacol       Date:  1973-06       Impact factor: 3.765

8.  The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies.

Authors:  E Jähnchen; T Meinertz; H J Gilfrich; U Groth; A Martini
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

9.  Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

Authors:  R J Lewis; W F Trager; K K Chan; A Breckenridge; M Orme; M Roland; W Schary
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

10.  Biotransformation and pharmacokinetics of acenocoumarol (Sintrom) in man.

Authors:  W Dieterle; J W Faigle; C Montigel; M Sulc; W Theobald
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

View more
  17 in total

Review 1.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 2.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.

Authors:  L Borgström; L Nyberg; S Jönsson; C Lindberg; J Paulson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

5.  Cimetidine-nicoumalone interaction in man: stereochemical considerations.

Authors:  T S Gill; K J Hopkins; J Bottomley; S K Gupta; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 6.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

7.  Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bioequivalence study.

Authors:  J Popović; M Mikov; V Jakovljević
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Apr-Jun       Impact factor: 2.441

8.  Active metabolites of acenocoumarol: do they contribute to the therapeutic effect?

Authors:  H H Thijssen; L G Baars
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

9.  Lack of effect of ponsinomycin on the pharmacokinetics of nicoumalone enantiomers.

Authors:  W Couet; B Istin; J P Decourt; I Ingrand; J Girault; J B Fourtillan
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

10.  Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.

Authors:  H J G Desirée van den Bongard; Rolf W Sparidans; David J P Critchley; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.